Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia

Qijing Bo, Fang Dong, Xianbin Li, Zhimin Wang, Xin Ma, Chuanyue Wang, Qijing Bo, Fang Dong, Xianbin Li, Zhimin Wang, Xin Ma, Chuanyue Wang

Abstract

Background: This study aimed to investigate prolactin related symptoms (PRS) in individuals with schizophrenia during risperidone maintenance treatment for one year, as well as to identify the risk factors for PRS.

Methods: In a multicenter, randomized, controlled, longitudinal study, clinically stabilized schizophrenia patients (N = 374) were randomized to a no-dose-reduction group (N = 129) and 4-week (N = 125) and 26-week (N = 120) reduction groups, in which the original dose was followed by a 50 % reduction over 8 weeks and subsequently maintained. PRS were assessed via a scale of prolactin related adverse events, which included 16 items: menstrual cycle, menstrual period, menstrual volume, menstrual irregularities, amenorrhea, dysmenorrhea, postpartum lactation, gynecomastia, breast tenderness, sexual dysfunction, decreased sexual desire, erectile dysfunction, ejaculatory dysfunction, impotence, increased body hair, and acne. The occurrence of PRS was assessed at baseline and monthly for six months, followed by every two months. A mixed model was used.

Results: PRS at baseline were reported in 18.4, 15.0, and 14.0 % of the 4-week, 26-week, and no-dose-reduction groups, respectively. Female gender, younger age at onset, and the Positive and Negative Syndrome Scale (PANSS) total scores at entry predicted the development of PRS. The mixed model indicated that PRS were more severe in females and at a high dose. In the 237 patients who remained in the study after one year, the incidence of PRS decreased to 9.6, 11.1, and 7.6 % in the 4-week, 26-week, and no-dose-reduction groups, respectively.

Conclusion: These findings indicate that the PRS severity was alleviated during the one year treatment period because of the dose reduction. Attention should focus on the side effects of hyperprolactinemia during long-term treatment, especially with a high dose, females, younger age at onset, and more severe patients.

Trial registration: ClinicalTrials.gov identifier: NCT00848432 . Registered February 19, 2009.

Keywords: Antipsychotics; Generalized linear mixed model (GLMM); Maintenance treatment; Prolactin related symptoms; Risperidone; Schizophrenia; Side effects.

Figures

Fig. 1
Fig. 1
Prevalence of PRS in patients who remained in treatment

References

    1. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291–314. doi: 10.2165/00003495-200464200-00003.
    1. Svestka J, Synek O, Tomanova J, Rodakova I, Cejpkova A. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett. 2007;28(6):881–8.
    1. Fric M, Laux G. Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine. Psychiatr Prax. 2003;30(Suppl 2):97–101.
    1. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–53.
    1. Li Y, Li H, Liu Y, Yan X, Yue Y, Qian M. Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study. Curr Med Res Opin. 2012;28(10):1725–32. doi: 10.1185/03007995.2012.728524.
    1. Wang ZM, Xiang YT, An FR, Correll CU, Ungvari GS, Wang CY, Lai KY, Bo QJ, Li Y, Zhong BL, et al. Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. Perspect Psychiatr Care. 2013;50:257–63. doi: 10.1111/ppc.12050.
    1. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(Suppl 2):55–68. doi: 10.1016/S0306-4530(02)00127-0.
    1. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;1:CD006626.
    1. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66(6):761–7. doi: 10.4088/JCP.v66n0614.
    1. de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41(3):674–86. doi: 10.1093/schbul/sbv001.
    1. Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The effects of antipsychotics on prolactin levels and women’s menstruation. Schizophr Res Treatment. 2013;2013:502697. doi: 10.1155/2013/502697.
    1. Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf) 2011;74(2):141–7. doi: 10.1111/j.1365-2265.2010.03814.x.
    1. O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70–5. doi: 10.1177/0269881107088439.
    1. Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25(5):415–29. doi: 10.1097/YCO.0b013e328355e1ac.
    1. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527–42. doi: 10.1517/14740338.2012.683523.
    1. Krysiak R, Kedzia A, Okopien B. Unfavorable effects of hyperprolactinemia in autoimmune endocrine disorders. Neuro Endocrinol Lett. 2012;33(3):298–300.
    1. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003;9(5):344–53. doi: 10.1097/00131746-200309000-00003.
    1. Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol. 2012;26(5 Suppl):42–51. doi: 10.1177/0269881112442016.
    1. Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr Res. 2009;114(1–3):6–16. doi: 10.1016/j.schres.2009.07.012.
    1. Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011;45(10):830–7. doi: 10.3109/00048674.2011.589044.
    1. Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, Liu TQ, Wang GH, Weng SM, Zhang HY, et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry. 2010;167(6):676–85. doi: 10.1176/appi.ajp.2009.09030358.
    1. Xiang YT, Wang CY, Weng YZ, Bo QJ, Chiu HF, Zhao JP, Liu TQ, Chan SS, Lee EH, Ungvari GS. Sex differences in patients with schizophrenia: a prospective, multi-center study. Psychiatry Res. 2010;177(3):294–8. doi: 10.1016/j.psychres.2010.03.014.
    1. Xiang YT, Wang CY, Ungvari GS, Kreyenbuhl JA, Chiu HF, Lai KY, Lee EH, Bo QJ, Dixon LB. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. Pharmacopsychiatry. 2011;44(4):135–41. doi: 10.1055/s-0031-1277178.
    1. Xiang YT, Wang CY, Chiu HF, Weng YZ, Bo QJ, Chan SS, Lee EH, Ungvari GS. Socio-demographic and clinical profiles of paranoid and nonparanoid schizophrenia: a prospective, multicenter study in China. Perspect Psychiatr Care. 2011;47(3):126–30. doi: 10.1111/j.1744-6163.2010.00281.x.
    1. Xiang YT, Wang CY, Weng YZ, Bo QJ, Chiu HF, Chan SS, Lee EH, Ungvari GS. Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study. Soc Psychiatry Psychiatr Epidemiol. 2011;46(12):1325–30. doi: 10.1007/s00127-010-0304-1.
    1. Bo QJ, Li XB, Wang ZM, Li AN, Ma X, Wang CY. Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study. J Clin Psychopharmacol. 2016;36(2):125–9. doi: 10.1097/JCP.0000000000000464.
    1. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10(3):799–812. doi: 10.2466/pr0.1962.10.3.799.
    1. Csernansky JG, Mahmoud R, Brenner R, USASG Risperidone A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16–22. doi: 10.1056/NEJMoa002028.
    1. He YL, Zhang MY. The positive and negative syndrome scale (PANSS) and its application (in Chinese) J Clin Psychiatry. 1997;7:353–5.
    1. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800–2. doi: 10.1093/biomet/75.4.800.
    1. Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen RC. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65(11):1491–8. doi: 10.4088/JCP.v65n1108.
    1. Margari L, Matera E, Petruzzelli MG, Simone M, Lamanna AL, Pastore A, Palmieri VO, Margari F. Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. Int Clin Psychopharmacol. 2015;30(2):103–8. doi: 10.1097/YIC.0000000000000063.
    1. Einarson TR, Hemels ME, Nuamah I, Gopal S, Coppola D, Hough D. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Ann Pharmacother. 2012;46(10):1322–30. doi: 10.1345/aph.1R123.
    1. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57–61. doi: 10.1097/00004714-199902000-00011.
    1. Lee BH, Kim YK. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):658–62. doi: 10.1016/j.pnpbp.2005.11.037.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit